Ftse Mib
36.267,63
1,25%
DAX
20.903,39
1,31%
S&P 500
5.996,66
1,00%
NASDAQ
19.630,20
1,51%
Bitcoin
102.961,24
-1,12%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Agios Pharmaceuticals Inc (AGIO) Agios Pharmaceuticals Inc (AGIO) Notizie

Agios Pharmaceuticals Inc

AGIO
32,42
0,60 (1,89%)
18 Gen 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
13/1/202513:00GLOBEAgios Announces Key 2025 Milestones for Innovative Rare..
08/1/202513:00GLOBEFDA Accepts Agios’ Supplemental New Drug Application for..
07/1/202523:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202512:36EDGAR2Form 8-K - Current report
03/1/202522:25EDGAR2Form 144 - Report of proposed sale of securities
03/1/202513:00GLOBEAgios to Present at the 43rd Annual J.P. Morgan Healthcare..
18/12/202413:00GLOBEEuropean Commission Adopts Positive Decision for Orphan..
13/12/202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202418:40GLOBEAgios Presents Positive Results from Phase 3 ENERGIZE-T..
14/11/202421:44EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
13/11/202422:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/11/202422:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/11/202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/11/202422:17EDGAR2Form 144 - Report of proposed sale of securities
07/11/202422:06EDGAR2Form 144 - Report of proposed sale of securities
05/11/202415:05GLOBEAgios to Present New Data on Mitapivat and Tebapivat in Rare..
31/10/202414:20EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
31/10/202411:56EDGAR2Form 8-K - Current report
31/10/202411:30GLOBEAgios Reports Business Highlights and Third Quarter 2024..
23/10/202413:00GLOBEAgios Completes Enrollment of Phase 3 RISE UP Study of..
17/10/202413:00GLOBEAgios to Webcast Conference Call of Third Quarter 2024..
30/9/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/9/202413:00GLOBEAgios Announces FDA Orphan Drug Designation Granted to..
05/9/202413:00GLOBEAgios to Present at the 2024 Cantor Global Healthcare..
13/8/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/8/202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/8/202423:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202422:08EDGAR2Form 144 - Report of proposed sale of securities
06/8/202423:50GLOBEAgios to Receive $1.1 Billion in Milestone Payments..
01/8/202415:49EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/8/202413:03EDGAR2Form 8-K - Current report
01/8/202412:31GLOBEAgios Reports Business Highlights and Second Quarter 2024..
01/8/202412:30GLOBEAgios Announces Results from Phase 3 ACTIVATE-KidsT Study of..
18/7/202413:00GLOBEAgios to Webcast Conference Call of Second Quarter 2024..
17/6/202423:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/6/202423:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/6/202423:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/6/202423:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/6/202423:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/6/202423:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/6/202414:45GLOBEAgios Presents Positive Results from Phase 3 ENERGIZE Study..
07/6/202422:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/6/202415:00GLOBEUpdated Time: Agios to Present at the Goldman Sachs 45th..
06/6/202401:50EDGAR2Form 144 - Report of proposed sale of securities
05/6/202422:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/6/202412:30GLOBEAgios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met..
30/5/202422:05GLOBEAgios to Present at the Goldman Sachs 45th Annual Global..
28/5/202413:09EDGAR2Form 8-K - Current report
28/5/202413:00GLOBEAgios Announces $905 Million Purchase Agreement for..
14/5/202416:00GLOBEAgios Pharmaceuticals to Present Clinical and Translational..
Apertura: 32,33 Min: 31,3863 Max: 32,81
Chiusura: 31,82

La tua Cronologia

NASDAQ
AGIO
Agios Pharmaceuticals
BIT
P12V05
BNP PARIBAS ISSUANCE
BIT
S32582
Societe Generale Effekten
UNSW
TEAMETH
TeamUp
ASE
TENERGY
Terna Energy
BIT
P1H9U3
BNP Paribas Issuance
BIT
F25175
Vontobel Financial Produ...
BIT
P1OGZ6
BNP Paribas Issuance
LBNK
DOGEZILLAUSDT
DogeZilla
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network